Eagle Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EGRX research report →
About the company
Eagle Pharmaceuticals, Inc. , a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company’s product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.
- CEO
- Michael Graves
- IPO
- 2014
- Employees
- 141
- HQ
- Woodcliff Lake, NJ, US
Price Chart
- Market Cap
- $8.82M
- P/E
- 0.24
- P/S
- 0.03
- P/B
- 0.04
- EV/EBITDA
- 0.27
- Div Yield
- 0.00%
- Gross Margin
- 70.01%
- Op Margin
- 25.57%
- Net Margin
- 11.26%
- ROE
- 17.39%
- ROIC
- 15.51%
- Revenue
- $316.61M · 0.00%
- Net Income
- $35.64M · 0.00%
- EPS
- $2.76 · 0.00%
- Op Income
- $80.96M
- FCF YoY
- -39.04%
- 52W High
- $3.87
- 52W Low
- $0.09
- 50D MA
- $0.46
- 200D MA
- $1.94
- Beta
- 0.63
- Avg Volume
- 3.88K
Get TickerSpark's AI analysis on EGRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 11, 24 | Krawtschuk Christopher | other | 0 |
| Feb 28, 24 | Tarriff Scott | other | 2,119 |
| Feb 27, 24 | Cahill Brian Joseph | other | 3,800 |
| Feb 27, 24 | Cahill Brian Joseph | other | 1,589 |
| Feb 27, 24 | Tarriff Scott | other | 12,950 |
| Feb 27, 24 | Tarriff Scott | other | 3,154 |
| Feb 2, 24 | Cahill Brian Joseph | other | 934 |
| Jan 5, 24 | Cahill Brian Joseph | other | 735 |
| Jan 5, 24 | Tarriff Scott | other | 4,322 |
| Dec 21, 23 | Graves Michael | other | 293,000 |
Our EGRX coverage
Recent articles, reports, and earnings notes.
No research on EGRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EGRX report →Similar companies
Peers in the same neighborhood.